Table of Contents Author Guidelines Submit a Manuscript
International Journal of Inflammation
Volume 2011, Article ID 908468, 13 pages
Review Article

Recent Advances in Underlying Pathologies Provide Insight into Interleukin-8 Expression-Mediated Inflammation and Angiogenesis

1Department of Orthopedic Surgery Spine Unit, First Affiliated Hospital of Dalian Medical University, 222 Zhongshan Road, Dalian, Liaoning 116011, China
2Department of Pathology and Pathophysiology, Dalian Medical University, 9 West Section Lvshun South Road, Lvshun District, Dalian, Liaoning 116044, China

Received 23 April 2011; Revised 15 August 2011; Accepted 6 September 2011

Academic Editor: B. L. Slomiany

Copyright © 2011 Basit Saleem Qazi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Interleukin-8 has long been recognized to have anti-inflammatory activity, which has been established in various models of infection, inflammation, and cancer. Several cell types express the receptor for the cytokine IL-8 and upon its recognition produce molecules that are active both locally and systemically. Many different types of cells, in particular monocytes, neutrophils, epithelial, fibroblast, endothelial, mesothelial, and tumor cells, secrete IL-8. Increased expression of IL-8 and/or its receptors has been characterized in many chronic inflammatory conditions, including psoriasis, ARDS, COPD, and RA as well as many cancers, and its upregulation often correlates with disease activity. IL-8 constitutes the CXC class of chemokines, a potent chemoattractant and activator of neutrophils and other immune cells. It is a proangiogenic cytokine that is overexpressed in many human cancers. Therefore, inhibiting the effects of IL-8 signaling may be a significant therapeutic intervention.